How to Get Provigil in Indiana: Prescriptions, Telehealth, and Pharmacies

What Is Provigil and Why Do Indiana Patients Seek It?

Provigil is the brand name for modafinil, a wakefulness-promoting agent first approved by the FDA in 1998. The FDA label covers three indications: narcolepsy, obstructive sleep apnea (as an adjunct to CPAP), and shift-work sleep disorder (SWSD). The full prescribing information is maintained in the FDA's drug database.

Clinical Efficacy

The key narcolepsy trial, conducted by the US Modafinil in Narcolepsy Multicenter Study Group (N=271), showed modafinil 200 mg and 400 mg significantly reduced daytime sleepiness versus placebo on the Epworth Sleepiness Scale (P<0.001). [1] A subsequent multicenter trial (N=558) replicated those findings and demonstrated that 400 mg produced a mean ESS reduction of 3.1 points from baseline. [2]

Mechanism of Action

Modafinil inhibits dopamine reuptake, raising synaptic dopamine concentrations in the hypothalamus and prefrontal cortex. Unlike amphetamines, it shows minimal affinity for norepinephrine, serotonin, or GABA receptors at therapeutic doses. [3] That selectivity accounts for its lower abuse potential compared with Schedule II stimulants, which is why the DEA placed it in Schedule IV rather than Schedule II. [4]

Off-Label Demand

Many Indiana patients request modafinil for cognitive fatigue associated with multiple sclerosis, cancer-related fatigue, or treatment-resistant depression augmentation. A 2021 meta-analysis in the Journal of Clinical Psychiatry (N=568 across 6 RCTs) found modafinil augmentation reduced depressive symptom scores by a standardized mean difference of 0.37 (95% CI 0.12 to 0.62). [5] Indiana Medicaid does not cover off-label modafinil use, so those patients pay out of pocket or use commercial insurance with prior authorization.

Indiana Telehealth Rules for Controlled Substance Prescribing

Indiana permits telehealth prescribing of Schedule IV controlled substances, including modafinil, provided the clinician establishes a valid patient-provider relationship before writing the prescription. Indiana Code 25-1-9.5 defines that relationship as requiring a clinician-conducted evaluation adequate to establish a diagnosis and identify contraindications.

What "Valid Patient-Provider Relationship" Means in Practice

A synchronous video visit (audio-video, not audio-only) typically satisfies the requirement for Schedule IV prescribing. The clinician must review the patient's medical history, relevant sleep study data if available, and current medication list. A physical exam is not mandated by Indiana statute for telehealth encounters, though many clinicians request recent lab panels or polysomnography results for narcolepsy cases.

Federal Overlay: The Ryan Haight Act

Federal law under the Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 829(e)) generally requires an in-person evaluation before a practitioner prescribes a controlled substance via the internet. The DEA issued temporary COVID-era flexibilities in 2020 allowing telehealth prescribing of Schedule III-V substances without a prior in-person visit. [6] As of the article's last-reviewed date, the DEA has proposed rules to extend some of those flexibilities; patients should confirm current status with their telehealth provider, because the regulatory field has changed multiple times. [7]

How Indiana Telehealth Platforms Work

Most telehealth platforms serving Indiana operate as follows. First, the patient completes an intake form covering sleep history, Epworth Sleepiness Scale self-assessment, comorbidities, and current medications. Second, a licensed Indiana clinician conducts a video visit, typically 15 to 30 minutes. Third, if modafinil is appropriate, the clinician sends an e-prescription via a DEA-registered electronic prescribing system. Fourth, the prescription routes to the patient's chosen pharmacy. Same-day e-prescribing is common when no prior authorization is needed.

Who Can Prescribe Provigil in Indiana?

Any Indiana-licensed prescriber with DEA Schedule IV authority may write a modafinil prescription.

Physicians (MD and DO)

Board-certified sleep medicine physicians, neurologists, and psychiatrists are the most common modafinil prescribers. Primary care MDs and DOs may prescribe it as well, provided they have conducted an appropriate evaluation. The American Academy of Sleep Medicine's 2023 clinical practice guidelines recommend modafinil as a first-line pharmacotherapy for narcolepsy type 1 and type 2. [8]

Nurse Practitioners

Indiana NPs may prescribe Schedule IV substances under full prescriptive authority granted after completing 2,000 supervised clinical hours and holding a valid DEA number. Indiana Code 25-23-1-19.5 governs NP prescriptive authority. NPs practicing via telehealth platforms in Indiana frequently prescribe modafinil for SWSD without physician co-signature.

Physician Assistants

PAs in Indiana prescribe controlled substances under a supervision agreement with a licensed physician. The supervising physician does not need to be present at the encounter but must be available for consultation. PAs may therefore prescribe modafinil via telehealth subject to their supervision agreement terms.

Step-by-Step: Getting a Provigil Prescription in Indiana

The path from first inquiry to first dose generally takes one to five business days, depending on insurance requirements.

Step 1: Gather Your Records

Collect any prior sleep study (polysomnography or multiple sleep latency test) results, previous prescription records for sleep or stimulant medications, and a list of current drugs including supplements. Modafinil interacts with CYP3A4 inducers and inhibitors; your prescriber will screen for rifampin, hormonal contraceptives (modafinil reduces ethinyl estradiol AUC by approximately 18%), and cyclosporine. [9]

Step 2: Choose a Telehealth Provider or Local Clinician

Indiana patients have two practical options. A local sleep medicine specialist can order a polysomnography before prescribing, which is the preferred path for suspected narcolepsy. A telehealth clinician can evaluate SWSD or fatigue-related presentations more quickly, often without requiring a sleep study for SWSD. Search the AASM's member finder for board-certified sleep medicine physicians accepting new Indiana patients.

Step 3: Complete the Clinical Evaluation

During the video visit, expect questions covering sleep schedule, severity of excessive daytime sleepiness (quantified by the Epworth scale), history of stimulant or substance use, cardiovascular history (modafinil carries a small risk of serious rash including Stevens-Johnson syndrome, estimated at 1 in 1,000 pediatric patients and lower in adults), and psychiatric history. [10]

Step 4: Handle Prior Authorization If Required

Commercial insurers operating in Indiana, including Anthem, UnitedHealthcare, and Cigna, typically require prior authorization for brand-name Provigil. Generic modafinil may or may not require PA depending on the plan formulary tier. The PA documentation generally includes a confirmed diagnosis code (G47.419 for narcolepsy without cataplexy, G47.411 with cataplexy), ESS score, and evidence of a clinical evaluation. Your clinician's office submits the PA; turnaround is usually 24 to 72 hours for urgent requests and up to 14 days for standard requests under Indiana's managed care rules.

Step 5: Fill the Prescription

Indiana retail pharmacies (CVS, Walgreens, Walmart, Kroger, independent pharmacies) all stock generic modafinil. Because it is Schedule IV, the prescription may be transmitted electronically; paper or fax is not required. Refills on Schedule IV prescriptions are permitted up to five times within six months of the original date under federal DEA rules (21 CFR 1306.23).

Labs and Testing Before Starting Modafinil

Routine laboratory work is not mandated by any guideline before initiating modafinil in otherwise healthy adults. Many Indiana clinicians order a baseline panel.

Common Pre-Treatment Tests

A basic metabolic panel checks renal and hepatic function, since modafinil is primarily hepatically metabolized via CYP3A4 and amide hydrolysis. Liver enzyme elevation has been reported in post-marketing data, though controlled trial rates were not significantly different from placebo. [11] A urine drug screen rules out concurrent stimulant use that could confound dosing decisions. Thyroid function (TSH) rules out hyperthyroidism as a cause of sleep disruption. For women of childbearing potential, pregnancy testing is standard given modafinil's potential teratogenic risk (FDA Pregnancy Category C under the old system). [12]

Sleep Studies

For narcolepsy specifically, the AASM recommends an overnight polysomnography followed by a multiple sleep latency test (MSLT) showing mean sleep latency <8 minutes with two or more sleep-onset REM periods. [13] Telehealth providers evaluating shift-work sleep disorder do not typically require a sleep study before prescribing modafinil.

Pharmacy Options in Indiana

Retail Pharmacies

All major retail chains in Indiana carry generic modafinil (200 mg tablets). The GoodRx cash price for 30 tablets of generic modafinil 200 mg hovers around $30, $50 at Indiana Walmart and Kroger locations as of mid-2025. Presenting a GoodRx or RxSaver coupon at the pharmacy counter typically produces a lower price than most commercial insurance co-pays for this drug.

Mail-Order Pharmacies

Mail-order pharmacies affiliated with commercial insurance PBMs (Express Scripts, CVS Caremark, OptumRx) ship Schedule IV substances to Indiana addresses. Processing takes three to five business days for a 90-day supply, which usually costs less per tablet than monthly retail fills.

503A Compounding Pharmacies

Indiana-licensed 503A compounding pharmacies may compound modafinil into alternative formulations (oral suspensions for patients with swallowing difficulties, for example) when a commercially available product is not clinically appropriate. The FDA's guidance on 503A pharmacies specifies they must receive a valid patient-specific prescription. [14] Compounded modafinil is not bioequivalent-certified and should not be used as a simple cost-saving substitute for commercial tablets when the commercial product is available.

The HealthRX clinical team uses a four-criteria checklist before recommending a 503A-compounded modafinil formulation to an Indiana patient: (1) documented swallowing difficulty or verified absorption disorder on record, (2) prescriber attestation that no commercially available formulation meets clinical needs, (3) the compounding pharmacy holds a current Indiana Board of Pharmacy 503A license, and (4) the patient understands compounded drugs lack FDA-reviewed bioequivalence data. All four criteria must be met.

Transferring an Existing Provigil Prescription to Indiana

Patients relocating to Indiana with an active modafinil prescription face a straightforward process. Because modafinil is Schedule IV, federal DEA regulations (21 CFR 1306.23) allow retail pharmacies to transfer Schedule IV prescriptions one time between pharmacies. The receiving Indiana pharmacy contacts the original pharmacy, verifies remaining refills, and processes the transfer.

If refills are exhausted or the original prescription is more than six months old, a new prescription from an Indiana-licensed prescriber is required. An existing patient chart, prior polysomnography reports, and a letter of medical necessity from the previous prescriber speed up the new evaluation considerably. Most telehealth platforms can complete this re-evaluation in a single video visit.

Insurance and Cost in Indiana

Commercial Insurance

Most large-group commercial plans in Indiana cover generic modafinil on Tier 2 or Tier 3 formulary, typically with co-pays of $10, $60 per 30-tablet fill after deductible. Brand-name Provigil is rarely covered because generics have been available since 2012. If your plan requires PA, expect to provide ESS documentation and the treating diagnosis code.

Indiana Medicaid (Healthy Indiana Plan)

Indiana Medicaid does not cover modafinil for off-label cognitive indications. Coverage for narcolepsy under the Healthy Indiana Plan (HIP) exists in principle but requires PA demonstrating a confirmed narcolepsy diagnosis with failed behavioral interventions. Approval rates for narcolepsy-indicated modafinil under HIP have not been published; anecdotally, Indiana sleep medicine specialists report moderate success with thorough MSLT documentation.

Medicare Part D

Medicare Part D plans vary. Generic modafinil appears on formulary in most Part D plans, typically at Tier 2 to 3 pricing. The Extra Help subsidy (Low Income Subsidy) reduces co-pays to $4.50 or $11.20 per fill (2025 LIS co-pay amounts) for qualifying Indiana beneficiaries. [15]

Safety, Side Effects, and Monitoring

Modafinil carries a generally favorable safety profile in adults. The most common adverse effects in controlled trials were headache (34% modafinil vs. 23% placebo), nausea (11% vs. 3%), nervousness (7% vs. 3%), and insomnia (5% vs. 1%). [1]

Serious Risks

Serious hypersensitivity reactions, including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported in post-marketing surveillance. The FDA added a warning to the Provigil label following these reports. [16] Patients should discontinue modafinil immediately and seek emergency care if they develop a rash, blistering, mouth sores, or fever within the first few weeks of treatment.

Modafinil may induce CYP3A4 and thereby reduce efficacy of hormonal contraceptives. Women using oral, transdermal, or implantable hormonal contraception should use a barrier method during modafinil treatment and for one month after discontinuation. [9]

Psychiatric Monitoring

Patients with a history of psychosis, bipolar disorder, or anxiety may experience symptom exacerbation. The AASM recommends caution and psychiatric consultation before initiating modafinil in those populations. [8] Indiana telehealth platforms typically flag psychiatric history during intake and route those patients to a psychiatry-trained clinician.

Cardiovascular Monitoring

Modafinil produced modest increases in mean heart rate (3 to 4 bpm) and blood pressure (1 to 3 mmHg systolic) in clinical trials. [2] Patients with pre-existing left ventricular hypertrophy, mitral valve prolapse, or arrhythmias were excluded from the key trials, so caution is warranted. A 2020 pharmacovigilance review of FDA Adverse Event Reporting System (FAERS) data found a disproportionality signal for palpitations and tachycardia with modafinil (reporting odds ratio 3.4, 95% CI 2.8 to 4.2). [17]

Dosing Reference for Indiana Prescribers and Patients

The FDA-approved doses are straightforward. For narcolepsy and obstructive sleep apnea: modafinil 200 mg orally once in the morning. The dose may be increased to 400 mg/day if the clinical response is insufficient, though the FDA notes that 400 mg did not confer additional benefit beyond 200 mg in some narcolepsy trials. [1] For shift-work sleep disorder: modafinil 200 mg taken approximately one hour before the start of the work shift.

Dose reduction to 100 mg is appropriate for patients with severe hepatic impairment (Child-Pugh Class C), elderly patients, or those taking CYP3A4 inhibitors such as ketoconazole or itraconazole. [9] No dose adjustment is required for renal impairment alone, though clinical trial data in severe renal impairment (creatinine clearance <20 mL/min) are limited.

The American Academy of Sleep Medicine's 2023 guideline states: "Modafinil and armodafinil are recommended as first-line pharmacologic treatments for narcolepsy-associated excessive daytime sleepiness, given their established efficacy and favorable tolerability compared with traditional stimulants." [8]